US 12,491,245 B2
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
Angeles Estelles, Belmont, CA (US); Lawrence M. Kauvar, San Francisco, CA (US); Adam Vigil, Yonkers, NY (US); and Michael Wittekind, Yonkers, NY (US)
Assigned to CONTRAFECT CORPORATION, Yonkers, NY (US); and TRELLIS BIOSCIENCE, INC, Redwood City, CA (US)
Filed by CONTRAFECT CORPORATION, Yonkers, NY (US); and TRELLIS BIOSCIENCE, INC., Redwood City, CA (US)
Filed on Dec. 23, 2021, as Appl. No. 17/560,830.
Application 16/674,149 is a division of application No. 15/116,106, granted, now 10,639,370, issued on May 5, 2020, previously published as PCT/US2015/014521, filed on Feb. 4, 2015.
Application 17/560,830 is a continuation of application No. 16/674,149, filed on Nov. 5, 2019, granted, now 11,246,928.
Claims priority of provisional application 62/051,630, filed on Sep. 17, 2014.
Claims priority of provisional application 61/935,746, filed on Feb. 4, 2014.
Prior Publication US 2022/0111049 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/42 (2006.01); A61K 39/00 (2006.01); C07K 16/10 (2006.01)
CPC A61K 39/42 (2013.01) [C07K 16/1018 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/543 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A pharmaceutical composition formulated for intranasal or inhalation administration and effective for treatment or prophylaxis of influenza viral infection in a subject comprising:
(a) a first antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising:
a heavy chain amino acid sequence comprising a heavy chain variable region (HCVR) comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 12 and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:13 and
a light chain amino acid sequence comprising a light chain variable region (LCVR) comprising a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 14, a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO: 15, and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO: 16;
(b) a second antibody or antigen-binding fragment thereof that binds to and/or inhibits influenza virus comprising: a heavy chain amino acid sequence comprising HCVR comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 21, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 22, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 23 and a light chain amino acid sequence comprising a LCVR comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO: 24, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 25, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 26; and
(c) a third antibody or antigen-binding fragment thereof that binds to one or more strains of each of influenza B Yamagata and influenza B Victoria clades comprising: a heavy chain amino acid sequence comprising a HCVR comprising: a heavy chain amino acid sequence comprising a HCVR comprising: a HCDR1 comprising the amino acid sequence of SEQ ID NO:241, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 242, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 243 and a light chain amino acid sequence comprising a LCVR comprising: a LCDR1 comprising the amino acid sequence of SEQ ID NO: 244, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 245, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 246.